Syringe Driver Survey Database migration to MedicinesComplete - January 2023

Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.

It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.

Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.

Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/

If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023. 

To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html

To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales

If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.

---

Instanyl (fentanyl) multidose nasal sprays discontinued

6th November 2018

Takeda UK is discontinuing all strengths of Instanyl^® (fentanyl citrate) multidose nasal sprays on the 14^th December 2018 for commercial reasons.

The single dose Instanyl^® products (50micorgram/mL, 100microgram/mL and 200micorgram/mL) will remain available.

Alternative transmucosal fentanyl citrate products are available including, sublingual (Abstral^®) and buccal (Effentora^®) tablets, a lozenge with oromucosal applicator (Actiq^®) and a nasal spray (Pecfent^®). However, these products are not interchangeable on a microgram per microgram basis from one product to another and patients must undergo full titration if switching to a new product.

See the PCF Fentanyl (transmucosal) monograph and individual SPCs for details.

Letter to healthcare professionals